Neith Corporation (TPEX:6236)
15.90
+0.80 (5.30%)
Aug 26, 2026, 11:15 AM CST
Neith Revenue
Neith had revenue of 8.07M TWD in the quarter ending June 30, 2026, a decrease of -2.30%. This brings the company's revenue in the last twelve months to 31.84M, down -23.34% year-over-year. In the year 2025, Neith had annual revenue of 36.15M, down -20.68%.
Revenue (ttm)
31.84M
Revenue Growth
-23.34%
P/S Ratio
19.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
628.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.15M | -9.43M | -20.68% |
| Dec 31, 2024 | 45.57M | 5.67M | 14.20% |
| Dec 31, 2023 | 39.90M | 7.85M | 24.48% |
| Dec 31, 2022 | 32.06M | 668.00K | 2.13% |
| Dec 31, 2021 | 31.39M | -12.35M | -28.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| BioLASCO Taiwan | 258.04M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 238.08M |
| NatureWise Biotech & Medicals | 174.62M |
| Vectorite Biomedical | 54.81M |
| Holy Stone Healthcare | 47.51M |